Maxim Group analyst Jason McCarthy maintained a Buy rating on Capricor Therapeutics (CAPR – Research Report) yesterday and set a price target of $12.00. The company’s shares closed yesterday at $4.03.
According to TipRanks, McCarthy is an analyst with an average return of -29.3% and a 19.64% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Achieve Life Sciences, and Lineage Therap.
Capricor Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $15.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $6.58 and a one-year low of $3.06. Currently, Capricor Therapeutics has an average volume of 75.49K.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CAPR in relation to earlier this year. Most recently, in February 2023, Earl Collier, a Director at CAPR bought 1,401.00 shares for a total of $1,947.39.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.
Read More on CAPR:
- Capricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
- CAPR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Capricor Therapeutics announces publication on StealthX Platform
- Capricor Therapeutics Presents at 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
- Capricor Therapeutics presents results from HOPE-2 OLE study of CAP-1002
